Japan approves rheumatoid drug Baricitinib for COVID-19 patients

TOKYO (Reuters) - Japan's health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co's Japan subsidiary had applied to regulators for the new use of the drug in December.

(Reporting by Rocky Swift; Editing by Clarence Fernandez)

(c) Copyright Thomson Reuters 2021. Click For Restrictions -

Reuters Japan Health United States Asia East Asia US